Call-On-Doc vs bmiMD
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Call-On-Doc
Best for: coverage in all 50 states, which most of the register will not confirm
Visit Call-On-Doc →
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD starts at $99/mo, and bmiMD finishes ahead, 9.1 to 4.7. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Call-On-Doc
Pricing not publicly listed.
bmiMD
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
What’s included
Call-On-Doc
Covered by the monthly price
Medication
Not stated
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
bmiMD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Call-On-Doc
4.7/10
bmiMD
9.1/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Call-On-Doc | bmiMD |
|---|---|---|
| Starting Price | — | $99/mo |
| Features | ✓8 features | 2 features |
| States Available | 50 | 50 |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About Call-On-Doc
Call-On-Doc runs a GLP-1 weight-loss program inside a broad multi-condition telehealth service that by its own account has 2M+ patients and 800k+ five-star reviews. Visits are flat-rate with no appointment needed, and the site says most finish within two hours, seven days a week, text consults included. Branded Wegovy, Ozempic, Mounjaro, Zepbound and Saxenda can be prescribed by board-certified providers across all 50 states plus DC. Insurance can be used at the pharmacy and an Rx savings card is offered.
Read our full Call-On-Doc review →About bmiMD
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Read our full bmiMD review →Pros & Cons
Call-On-Doc
What we like
- The monthly figure covers consult
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
bmiMD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
bmiMD takes it, 9.1 against 4.7, and it is especially strong on starting below a standard dose, with microdose tiers. Call-On-Doc is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.
Choose Call-On-Doc if…
You want coverage in all 50 states, which most of the register will not confirm.
Choose bmiMD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →YourEra
Semaglutide at $99/month, 63% under the register median
From $99/mo
Get started →Gala
Moving between compounded and brand without changing seller
From $129/mo
Get started →Call-On-Doc vs bmiMD: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Call-On-Doc and bmiMD head-to-heads in the same category.
- Call-On-Doc vs Trimi Health
- Call-On-Doc vs Embody
- Call-On-Doc vs He & She MD
- bmiMD vs Lean Meds
- bmiMD vs NextMeds
- bmiMD vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.